Platelet Immunobiology studies the pathogenic immune mechanisms responsible for platelet disorders related to alloantibodies or autoantibodies against platelets. Platelet disorders caused by antibodies against platelets include immune thrombocytopenia, fetal/neonatal alloimmune thrombocytopenia, drug-induced immune thrombocytopenia, and platelet-transfusion refractoriness. Rapid and precise diagnosis using reliable platelet serology testing is mandatory to avoid severe clinical consequences for patients. Understanding the underlying mechanisms is a key to better treatment or prophylaxis.
We provide access to like-minded colleagues active in (diagnostic) laboratory, research and/or clinical settings in all aspects of platelet immunobiology. We promote basic and clinical research to improve the knowledge on antibody-mediated platelet disorders and to improve laboratory testing and clinical guidance. We set standards for serological testing, diagnostic pathways, and clinical decision making in patients with antibody-mediated platelet disorders.
To reach our aims, we establish and monitor nomenclature for human platelet alloantigens (HPA) and support scientific co-operation between our members. We encourage and support new and emerging platelet immunology laboratories through education and organisation of practical workshop sessions.
Our Chairpersons are Ulrich J. Sachs and Nelson H. Tsuno.
We meet at ISBT congresses. We organise international workshops every other year. Also, we regularly organise the exchange of typing material and test protocols. We have installed sub-committees on Quality and Clinical Guidance and invite ISBT members with interest in the field to actively participate.
Membership is open to all ISBT members actively working in a (diagnostic) laboratory, research, or clinical setting of the field of Platelet Immunobiology. Employees of pharmaceutical companies are allowed to attend our meetings; however, they cannot become a WP member nor actively participate in a workshop.
- Bleeding or no bleeding? Anti‐endothelial alphaVbeta3 antibodies as a major cause of intracranial haemorrhage in fetal–neonatal alloimmune thrombocytopeniaISBT Science Series 2017 Dec; 13, 59–69
- Report on the 18th Platelet Immunology Workshop of the ISBT 2016ISBT Science Series, February 2017, Pages: 214–222
- Antiendothelial αvβ3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune ThrombocytopeniaArteriosclerosis, Thrombosis, and Vascular Biology, Aug 1 2016
- Report on the 16th international society of blood transfusion platelet immunology workshop.ISBT Science Series 2014; 9(2):295-303
- Report on the 15th International Society of Blood Transfusion platelet immunology workshop.Vox Sang. 2012 Nov;103(4):343-51.
Find a list of drugs that were previously identified as inducers of drug-dependent antiplatelet antibodies here.
Fetal/neonatal alloimmune thrombocytopenia
NAITbabies.org is a charitable organization run by families affect by FNAIT. Parents and relatives will find news, family stories, blogs, and a private parents' forum here.
- Webcast: Platelet transfusion alloimmunization: causes, consequences and coping, Anneke Brand, 2020
- Webcast: Role of extracellular vesicles in platelet transfusion medicine, Eric Boilard, 2017
- Webcast: Platelet Immunology, John Semple, 2017
- Webcast: The importance of platelet antigens and antibodies in immune mediated thrombocytopenia, Nelson Tsuno, 2013